loading...| Preferred Name | Alectinib | |
| Synonyms |
ALK Inhibitor RO5424802 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- AF-802 AF802 ALECTINIB Alecensa Alectinib CH5424802 RG7853 RO5424802 |
|
| Definitions |
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101790 |
|
| Accepted_Therapeutic_Use_For |
anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) |
|
| CAS_Registry |
1256580-46-7 |
|
| CHEBI_ID |
CHEBI:62268 |
|
| code |
C101790 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors. |
|
| Display_Name |
Alectinib |
|
| FDA_UNII_Code |
LIJ4CT1Z3Y |
|
| FULL_SYN |
ALK Inhibitor RO5424802 5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo- AF-802 AF802 ALECTINIB Alecensa Alectinib CH5424802 RG7853 RO5424802 |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Alectinib |
|
| Maps_To |
Alectinib |
|
| NCI_Drug_Dictionary_ID |
733572 |
|
| PDQ_Closed_Trial_Search_ID |
733572 |
|
| PDQ_Open_Trial_Search_ID |
733572 |
|
| Preferred_Name |
Alectinib |
|
| prefixIRI |
Thesaurus:C101790 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C3853921 |
|
| subClassOf |